NL300757I2 - - Google Patents
Download PDFInfo
- Publication number
- NL300757I2 NL300757I2 NL300757C NL300757C NL300757I2 NL 300757 I2 NL300757 I2 NL 300757I2 NL 300757 C NL300757 C NL 300757C NL 300757 C NL300757 C NL 300757C NL 300757 I2 NL300757 I2 NL 300757I2
- Authority
- NL
- Netherlands
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/655,760 US6414016B1 (en) | 2000-09-05 | 2000-09-05 | Anti-constipation composition |
| PCT/JP2001/007628 WO2002020007A1 (en) | 2000-09-05 | 2001-09-04 | Cathartic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL300757I2 true NL300757I2 (nl) | 2015-12-29 |
| NL300757I1 NL300757I1 (nl) | 2015-12-29 |
Family
ID=24630250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300757C NL300757I1 (nl) | 2000-09-05 | 2015-08-28 |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US6414016B1 (nl) |
| EP (2) | EP1315485B1 (nl) |
| JP (3) | JP2004508327A (nl) |
| KR (2) | KR100918223B1 (nl) |
| CN (1) | CN100335049C (nl) |
| AR (2) | AR030609A1 (nl) |
| AT (1) | ATE476975T1 (nl) |
| AU (2) | AU2001282615B2 (nl) |
| BR (1) | BRPI0114042B8 (nl) |
| CA (1) | CA2419741C (nl) |
| CZ (1) | CZ304740B6 (nl) |
| DE (2) | DE60142810D1 (nl) |
| DK (2) | DK1315485T3 (nl) |
| ES (2) | ES2296786T3 (nl) |
| HU (1) | HU229319B1 (nl) |
| IL (2) | IL154534A0 (nl) |
| MX (1) | MXPA03001959A (nl) |
| NL (1) | NL300757I1 (nl) |
| NO (1) | NO332701B1 (nl) |
| NZ (1) | NZ524401A (nl) |
| PT (2) | PT1857105E (nl) |
| RU (1) | RU2694361C3 (nl) |
| TW (1) | TWI305147B (nl) |
| WO (1) | WO2002020007A1 (nl) |
| ZA (1) | ZA200301673B (nl) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1220849T3 (da) * | 1999-10-15 | 2004-09-27 | Sucampo Ag | Sammensætninger med bicykliske forbindelser og fremgangsmåde til stabilisering heraf |
| US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| AR037524A1 (es) * | 2001-11-14 | 2004-11-17 | Sucampo Ag | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion |
| US7732487B2 (en) * | 2001-11-19 | 2010-06-08 | Sucampo Ag | Method for treating a disease or condition responsive to opening of C1C-2 channel |
| US8114911B2 (en) * | 2002-10-23 | 2012-02-14 | Sucampo Ag | Prostaglandin compounds for the treatment of obesity |
| NZ541110A (en) * | 2002-12-27 | 2008-11-28 | Sucampo Ag | Derivatives of prostaglandins for treating abdominal discomfort |
| EP1641462B1 (en) | 2003-07-03 | 2010-11-24 | Sucampo AG | Enteric coated composition comprising prostaglandin analogs as chloride channel opener |
| TWI348386B (en) * | 2003-08-12 | 2011-09-11 | R Tech Ueno Ltd | Composition and method for promoting hair growth |
| TWI387454B (zh) * | 2004-09-02 | 2013-03-01 | Sucampo Ag | 治療胃腸道疾病之方法及組成物 |
| CN101146541B (zh) | 2005-01-27 | 2012-04-11 | 苏坎波公司 | 用于治疗中枢神经系统疾病的方法和组合物 |
| DK1853271T3 (da) * | 2005-03-04 | 2011-01-24 | Sucampo Ag | Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme |
| WO2006096626A2 (en) * | 2005-03-07 | 2006-09-14 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US20060281818A1 (en) | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| ES2371658T3 (es) * | 2005-04-12 | 2012-01-05 | Sucampo Ag | Uso combinado de compuesto de prostaglandina e inhibidor de la bomba de protones para el tratamiento de trastornos gastrointestinales. |
| JP5265369B2 (ja) * | 2006-01-24 | 2013-08-14 | 株式会社アールテック・ウエノ | 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法 |
| EP2735566A1 (en) * | 2006-02-07 | 2014-05-28 | R-Tech Ueno, Ltd. | Method for preparing prostaglandin derivative |
| US20090012165A1 (en) * | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
| US20090030072A1 (en) | 2007-07-03 | 2009-01-29 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
| US20090082442A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched lubiprostone |
| CN101318948B (zh) * | 2008-04-01 | 2011-04-27 | 上海天伟生物制药有限公司 | 鲁比前列酮晶体、其制备方法及用途 |
| US8513441B2 (en) * | 2008-08-29 | 2013-08-20 | Alphora Research Inc. | Prostaglandin synthesis and intermediates for use therein |
| JP6113954B2 (ja) * | 2008-10-31 | 2017-04-12 | リピッド ファーマシューティカルズ イーエイチエフ． | 医薬として使用するための脂肪酸 |
| LT2384318T (lt) | 2008-12-31 | 2018-02-26 | Ardelyx, Inc. | Junginiai ir būdai, skirti nhe-medijuoto antiporto slopinimui, gydant sutrikimus, susijusius su skysčių kaupimusi ir druskų pertekliumi, bei virškinamojo trakto sutrikimus |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CA2750487A1 (en) | 2009-01-22 | 2010-07-29 | Apotex Pharmachem Inc. | Methods of making lubiprostone and intermediates thereof |
| US9084815B2 (en) * | 2009-09-16 | 2015-07-21 | Sucampo Ag | Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor |
| CA2774021A1 (en) * | 2009-09-18 | 2011-03-24 | Adolor Corporation | Use of opioid receptor antagonist for gastrointestinal tract disorders |
| WO2011054087A1 (en) * | 2009-11-03 | 2011-05-12 | Bernard Charles Sherman | Stable pharmaceutical formulations comprising lubiprostone |
| EP2516412A4 (en) * | 2009-12-18 | 2013-05-29 | Apotex Pharmachem Inc | PROCESS FOR CLEANING LUBIPROSTON |
| WO2011091513A1 (en) | 2010-01-28 | 2011-08-04 | Apotex Pharmachem Inc. | Polymorphic forms of lubiprostone |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| AU2013304812B2 (en) | 2012-08-21 | 2016-06-09 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| EP3988120A1 (en) | 2013-04-12 | 2022-04-27 | Ardelyx, Inc. | Nhe3-binding compounds and methods for inhibiting phosphate transport |
| EP3277274A4 (en) | 2015-04-01 | 2018-12-05 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
| AR105029A1 (es) * | 2015-06-19 | 2017-08-30 | Sucampo Ag | Composición farmacéutica que comprende derivado de ácido graso |
| US11534404B2 (en) | 2016-10-06 | 2022-12-27 | Sucampo Ag | Multilayer beads for pharmaceutical use |
| KR20190128626A (ko) | 2017-01-09 | 2019-11-18 | 알데릭스, 인코포레이티드 | Nhe-매개 역수송의 저해제 |
| JP7292207B2 (ja) | 2017-01-09 | 2023-06-16 | アルデリックス， インコーポレイテッド | 消化管障害を処置するために有用な化合物 |
| JP6750733B2 (ja) * | 2017-04-20 | 2020-09-02 | 株式会社島津製作所 | 分光光度計 |
| US10422729B1 (en) | 2019-03-08 | 2019-09-24 | Biodesix, Inc. | Blood sample separation devices and methods |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5720305B2 (nl) | 1973-02-28 | 1982-04-27 | ||
| US4034003A (en) | 1974-04-11 | 1977-07-05 | Ono Pharmaceutical Co., Ltd. | 15-Cycloalkyl-prostaglandins |
| JPS5350141A (en) | 1976-10-18 | 1978-05-08 | Ono Pharmaceut Co Ltd | Stabilization of prostaglandin and prostaglandin analogues |
| JPS5391110A (en) | 1977-01-20 | 1978-08-10 | Yamanouchi Pharmaceut Co Ltd | Novel drug composition for rectal infusion |
| JPS6022708B2 (ja) | 1977-07-14 | 1985-06-03 | 小野薬品工業株式会社 | プロスタグランジン類似化合物 |
| US4308595A (en) * | 1979-12-19 | 1981-12-29 | International Business Machines Corporation | Array driver |
| US4670569A (en) | 1981-04-02 | 1987-06-02 | G. D. Searle & Co. | 5-fluoro-PGI2 compounds |
| US4579958A (en) | 1983-12-23 | 1986-04-01 | G. D. Searle & Co. | 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds |
| US4687864A (en) | 1983-12-23 | 1987-08-18 | G. D. Searle & Co. | 5-fluoro-3-oxa-prostacyclin compounds |
| US5166174A (en) * | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| JPH0681728B2 (ja) * | 1987-10-02 | 1994-10-19 | 株式会社上野製薬応用研究所 | 下 剤 |
| US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
| GB2210556B (en) | 1987-10-02 | 1991-07-17 | Ueno Seiyaku Oyo Kenkyujo Kk | The use of 15-keto-16-halo-prostaglandins in cathartic compositions |
| JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体 |
| CA2030346C (en) * | 1989-11-22 | 2000-04-11 | Ryuji Ueno | Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds |
| CA2030345C (en) | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
| DE69130586T2 (de) * | 1990-05-01 | 1999-06-17 | R Tech Ueno Ltd | Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten |
| JP2515442B2 (ja) * | 1990-05-01 | 1996-07-10 | 株式会社上野製薬応用研究所 | 膵臓疾患処置剤 |
| JP2938579B2 (ja) | 1990-12-15 | 1999-08-23 | 株式会社上野製薬応用研究所 | 消化管壁保護剤 |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| US5958876A (en) * | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
| AUPO665397A0 (en) * | 1997-05-07 | 1997-05-29 | Borody, Thomas Julius | Novel therapy for constipation |
| WO1999045934A1 (fr) * | 1998-03-11 | 1999-09-16 | Grelan Pharmaceutical Co., Ltd. | Preparations entero-solubles effervescentes |
| US6471085B1 (en) | 1999-10-04 | 2002-10-29 | Anthony J. Gallo | Temperature cup |
| DK1220849T3 (da) * | 1999-10-15 | 2004-09-27 | Sucampo Ag | Sammensætninger med bicykliske forbindelser og fremgangsmåde til stabilisering heraf |
| EP1305396B1 (de) * | 2000-07-14 | 2005-11-02 | Henkel Kommanditgesellschaft auf Aktien | Kompartiment-hohlkörper enthaltend wasch-, reinigungs- oder spülmittelportion |
| US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
-
2000
- 2000-09-05 US US09/655,760 patent/US6414016B1/en not_active Expired - Lifetime
-
2001
- 2001-09-04 DK DK01961333T patent/DK1315485T3/da active
- 2001-09-04 KR KR1020087021218A patent/KR100918223B1/ko active Protection Beyond IP Right Term
- 2001-09-04 DE DE60142810T patent/DE60142810D1/de not_active Expired - Lifetime
- 2001-09-04 CA CA2419741A patent/CA2419741C/en not_active Expired - Lifetime
- 2001-09-04 RU RU2003109622A patent/RU2694361C3/ru active Protection Beyond IP Right Term
- 2001-09-04 AT AT07016834T patent/ATE476975T1/de active
- 2001-09-04 DE DE60131547T patent/DE60131547T2/de not_active Expired - Lifetime
- 2001-09-04 DK DK07016834.9T patent/DK1857105T3/da active
- 2001-09-04 MX MXPA03001959A patent/MXPA03001959A/es active IP Right Grant
- 2001-09-04 PT PT07016834T patent/PT1857105E/pt unknown
- 2001-09-04 JP JP2002524492A patent/JP2004508327A/ja active Pending
- 2001-09-04 TW TW090121835A patent/TWI305147B/zh not_active IP Right Cessation
- 2001-09-04 WO PCT/JP2001/007628 patent/WO2002020007A1/en active IP Right Grant
- 2001-09-04 ES ES01961333T patent/ES2296786T3/es not_active Expired - Lifetime
- 2001-09-04 AU AU2001282615A patent/AU2001282615B2/en not_active Expired
- 2001-09-04 EP EP01961333A patent/EP1315485B1/en not_active Expired - Lifetime
- 2001-09-04 BR BRPI0114042A patent/BRPI0114042B8/pt not_active IP Right Cessation
- 2001-09-04 AU AU8261501A patent/AU8261501A/xx active Pending
- 2001-09-04 CN CNB018183239A patent/CN100335049C/zh not_active Ceased
- 2001-09-04 IL IL15453401A patent/IL154534A0/xx unknown
- 2001-09-04 EP EP07016834A patent/EP1857105B1/en not_active Expired - Lifetime
- 2001-09-04 HU HU0302422A patent/HU229319B1/hu unknown
- 2001-09-04 ES ES07016834T patent/ES2347697T3/es not_active Expired - Lifetime
- 2001-09-04 PT PT01961333T patent/PT1315485E/pt unknown
- 2001-09-04 KR KR1020037003261A patent/KR100901102B1/ko active Protection Beyond IP Right Term
- 2001-09-04 CZ CZ2003-787A patent/CZ304740B6/cs not_active IP Right Cessation
- 2001-09-04 NZ NZ524401A patent/NZ524401A/en not_active IP Right Cessation
- 2001-09-05 AR ARP010104216A patent/AR030609A1/es unknown
-
2002
- 2002-05-06 US US10/138,650 patent/US6610732B2/en not_active Expired - Fee Related
-
2003
- 2003-02-19 IL IL154534A patent/IL154534A/en not_active IP Right Cessation
- 2003-02-28 ZA ZA200301673A patent/ZA200301673B/xx unknown
- 2003-03-04 NO NO20030996A patent/NO332701B1/no not_active IP Right Cessation
- 2003-05-22 US US10/443,046 patent/US20030216465A1/en not_active Abandoned
-
2005
- 2005-06-02 US US11/142,251 patent/US8071613B2/en not_active Expired - Fee Related
-
2009
- 2009-03-04 JP JP2009050902A patent/JP4684334B2/ja not_active Expired - Fee Related
- 2009-09-15 JP JP2009213058A patent/JP2009286806A/ja active Pending
-
2011
- 2011-10-17 US US13/274,612 patent/US8114890B1/en not_active Expired - Lifetime
- 2011-12-27 US US13/337,488 patent/US8748454B2/en not_active Expired - Fee Related
-
2013
- 2013-08-26 AR ARP130103006A patent/AR100291A2/es not_active Application Discontinuation
-
2014
- 2014-04-30 US US14/265,467 patent/US20140235665A1/en not_active Abandoned
-
2015
- 2015-08-28 NL NL300757C patent/NL300757I1/nl unknown